Expand ARQT Menu
ARQT MENU

ARQT Latest Press Releases

-- October 24, 2024 --

Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting Globe Newswire 8:00 AM

-- October 23, 2024 --

Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference Globe Newswire 4:00 PM

-- October 18, 2024 --

Arcutis Announces Health Canada Approval of ZORYVE (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older Globe Newswire 8:20 AM

-- October 4, 2024 --

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:00 PM

-- September 25, 2024 --

New Data Shows ZORYVE (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types Globe Newswire 1:00 AM

-- September 24, 2024 --

FDA Accepts Arcutis' Supplemental New Drug Application for ZORYVE (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over Globe Newswire 8:00 AM

-- September 19, 2024 --

Arcutis Announces Publication of ZORYVE (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology Globe Newswire 8:00 AM

-- September 5, 2024 --

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:00 PM
Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255 Globe Newswire 8:00 AM

-- August 28, 2024 --

Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis Globe Newswire 8:00 AM

-- August 22, 2024 --

Arcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference Globe Newswire 8:00 AM

-- August 14, 2024 --

Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update Globe Newswire 4:00 PM

-- August 2, 2024 --

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:00 PM

-- August 1, 2024 --

Arcutis to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024 Globe Newswire 4:00 PM

-- July 29, 2024 --

Arcutis Announces ZORYVE U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc. Globe Newswire 7:35 AM
Arcutis Launches ZORYVE (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis Globe Newswire 7:30 AM

-- July 23, 2024 --

Arcutis Submits Supplemental New Drug Application for ZORYVE (roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over Globe Newswire 8:00 AM

-- July 22, 2024 --

Arcutis to Host ZORYVE (Roflumilast) Cream 0.15% FDA Approval Call With KOL Globe Newswire 8:00 AM

-- July 9, 2024 --

FDA Approves Arcutis' ZORYVE (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age Globe Newswire 4:53 PM
Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic Dermatitis Globe Newswire 8:00 AM

-- July 3, 2024 --

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:00 PM

-- June 10, 2024 --

Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference Globe Newswire 2:30 PM

-- June 5, 2024 --

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:00 PM
Arcutis Announces Multiple Abstracts, Including Oral Presentation, Accepted at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference Globe Newswire 8:00 AM

-- June 3, 2024 --

Arcutis to Present at the Goldman Sachs 45th Annual Global Healthcare Conference Globe Newswire 8:00 AM